CX3CR1 and rheumatoid arthritis: Wang et al. showed that IA administration of AD-MSCs attenuates RA progression by suppressing pro-inflammatory cytokines, and mitigating neutrophil infiltration and cartilage erosion, as well as promotes the reconstruction of the CX3CR1+ synovial macrophage barrier in serum-transfer arthritis model mice [70].